Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication—from IFN based era to IFN-free DAA era

Toru Ishikawa


Chronic hepatitis C virus (HCV) infection is a public health issue which effects people throughout the world, with more than 71 million people effected, and 400,000 deaths annually (1). HCV, which is when active carriage of HCV RNA is in the blood, is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (2).